clinical trials

Cognition Therapeutics Announces First Patient Dosed in SEQUEL Study of CT1812

Pittsburgh, August 27, 2020 — Cognition Therapeutics, Inc., a clinical stage neuroscience company developing drugs that treat neurodegenerative disorders by regulating cellular damage response pathways announced that it has dosed the first patient in the SEQUEL (Study of EEG QUantification with ELayta) Study of CT1812 (Elayta™) in adults with mild-to-moderate Alzheimer’s disease. The study is …

Cognition Therapeutics Announces First Patient Dosed in SEQUEL Study of CT1812 Read More »

Cognition Therapeutics Receives $75.8 Million NIA Grant for 540-Patient Phase 2 Study of CT1812 in Collaboration with the Alzheimer’s Clinical Trials Consortium

New York, June 8, 2020 — Cognition Therapeutics, Inc., a clinical stage neuroscience company focused on the protection and restoration of synaptic function in Alzheimer’s disease and other neurodegenerative disorders, today announced that the National Institute on Aging (NIA) of the National Institutes of Health (NIH) has awarded the Company a grant (number R01AG065248) expected …

Cognition Therapeutics Receives $75.8 Million NIA Grant for 540-Patient Phase 2 Study of CT1812 in Collaboration with the Alzheimer’s Clinical Trials Consortium Read More »

Cognition Therapeutics Expands Clinical Expertise on Medical Advisory Board with Addition of Drs. Mary Sano and Philip Scheltens

Pittsburgh, April 05, 2019 — Cognition Therapeutics, Inc., a clinical stage neuroscience company focused on the protection and restoration of synaptic function in neurodegenerative diseases and disorders caused by membrane trafficking dysfunction, today announced that Mary Sano, Ph.D. of Mount Sinai School of Medicine and Philip Scheltens, M.D., Ph.D. of the VU Medical Center (VUmc) …

Cognition Therapeutics Expands Clinical Expertise on Medical Advisory Board with Addition of Drs. Mary Sano and Philip Scheltens Read More »

Cognition Therapeutics Elects Lisa Ricciardi to its Board of Directors

Pittsburgh, March 26, 2019 — Cognition Therapeutics, Inc., a clinical stage neuroscience company focused on the protection and restoration of synaptic function in neurodegenerative diseases and disorders caused by membrane trafficking dysfunction, today announced the appointment of Lisa Ricciardi to its Board of Directors. Ms. Ricciardi is a life sciences executive with broad industry experience, …

Cognition Therapeutics Elects Lisa Ricciardi to its Board of Directors Read More »

Cognition Therapeutics Announces Publication of Complete Results from Phase 1 Clinical Trial of Elayta™

Pittsburgh, Feb. 19, 2019 — Cognition Therapeutics, Inc., a clinical stage neuroscience company focused on the protection and restoration of synaptic function in neurodegenerative disorders, announced today the publication of clinical data from the Company’s Phase 1 trial of Elayta™ (CT1812) in Alzheimer’s & Dementia: Translational Research & Clinical Interventions. Top-line findings from this two-part randomized, …

Cognition Therapeutics Announces Publication of Complete Results from Phase 1 Clinical Trial of Elayta™ Read More »

Cognition Therapeutics Expands Industry-Leading Expertise in Research and Clinical Use of Biomarkers of Alzheimer’s Disease

Pittsburgh, Nov. 27, 2018 — Cognition Therapeutics, Inc., a clinical stage neuroscience company focused on the protection and restoration of synaptic function in neurodegenerative disorders, today announced the addition of three renowned leaders in imaging and molecular biomarkers to the company’s Medical Advisory Board. The global thought leaders, Kaj Blennow, M.D., Ph.D. and Henrik Zetterberg, …

Cognition Therapeutics Expands Industry-Leading Expertise in Research and Clinical Use of Biomarkers of Alzheimer’s Disease Read More »

Cognition Therapeutics Initiates Patient Dosing in Phase 2 SHINE Study of Elayta™ in Patients with Mild-to-Moderate Alzheimer’s Disease

PITTSBURGH, Nov 8, 2018 — Cognition Therapeutics, Inc., a clinical stage neuroscience company focused on synaptic protection and restoration in Alzheimer’s disease and other neurodegenerative disorders, today announced that patient treatment has begun in the Phase 2 SHINE study of Elayta™ (CT1812), Cognition’s lead candidate for the treatment of mild-to-moderate Alzheimer’s disease. SHINE (Synaptic Health and Improvement of Neurological …

Cognition Therapeutics Initiates Patient Dosing in Phase 2 SHINE Study of Elayta™ in Patients with Mild-to-Moderate Alzheimer’s Disease Read More »

Cognition Therapeutics Presents Additional Elayta™ Clinical Results during Alzheimer’s Association International Conference (AAIC) Symposium Session

Pittsburgh, July 23, 2018 — Cognition Therapeutics, Inc., a clinical stage neuroscience company focused on synaptic health and restoration in neurodegenerative disorders, today announced that co-founder and Chief Science Officer Susan Catalano, Ph.D. presented additional findings supporting the unique synaptorestorative mechanism of action of Elayta™ (CT1812), Cognition’s lead candidate for the treatment of mild-to-moderate Alzheimer’s disease, at the Alzheimer’s …

Cognition Therapeutics Presents Additional Elayta™ Clinical Results during Alzheimer’s Association International Conference (AAIC) Symposium Session Read More »

Cognition Therapeutics Initiates NIA-Funded SPARC Study of Elayta™ to Assess Changes in Synaptic Density and Cognitive Performance in Alzheimer’s Disease

First Longitudinal Study of Novel Synaptic Imaging Agent at Yale Alzheimer’s Disease Research Unit and Yale PET Center PITTSBURGH, June 18, 2018 — Cognition Therapeutics, Inc., a clinical stage neuroscience company focused on synaptic health and restoration in neurocognitive disorders, today announced that patient dosing has begun in the SPARC (Synaptic Protection for Alzheimer’s Restoration of Cognition) study of …

Cognition Therapeutics Initiates NIA-Funded SPARC Study of Elayta™ to Assess Changes in Synaptic Density and Cognitive Performance in Alzheimer’s Disease Read More »

Cognition Therapeutics Initiates NIA-Funded SNAP study of Elayta™ to Measure Toxic Oligomer Displacement and Clearance in Alzheimer’s Disease

PITTSBURGH, June 5, 2018 — Cognition Therapeutics, Inc., a clinical stage neuroscience company focused on the development of innovative therapeutics for the treatment of Alzheimer’s disease and other neurocognitive disorders, today announced that the first patient has been dosed in the SNAP (AβO Displacement from Synapses on Neurons in Alzheimer’s Patients) Study of Elayta™ (CT1812), Cognition’s lead candidate for …

Cognition Therapeutics Initiates NIA-Funded SNAP study of Elayta™ to Measure Toxic Oligomer Displacement and Clearance in Alzheimer’s Disease Read More »

Scroll to Top